-
1Academic Journal
Authors: M. V. Zamergrad, V. A. Parfenov, O. D. Ostroumova, A. L. Guseva, O. V. Zaytseva, Yu. P. Sivolap, I. V. Kukes, V. A. Voronov, М. В. Замерград, В. А. Парфенов, О. Д. Остроумова, А. Л. Гусева, О. В. Зайцева, Ю. П. Сиволап, И. В. Кукес, В. А. Воронов
Contributors: The expert council on functional dizziness was held by the Association of Interdisciplinary Medicine with the support of “Valenta Pharm” JSC, Совет экспертов по функциональному головокружению был проведен Ассоциацией междисциплинарной медицины при поддержке компании АО «Валента Фарм»
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 4-13 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 4-13 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4
Subject Terms: селективные ингибиторы обратного захвата серотонина, functional dizziness, persistent postural perceptual dizziness, buspirone, selective serotonin reuptake inhibitors, функциональное головокружение, персистирующее перцептивное постуральное головокружение, буспирон
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2326/1696; Strupp M, Dlugaiczyk J, Ertl-Wagner BB, et al. Vestibular Disorders. Dtsch Arztebl Int. 2020 Apr 24;117(17):300-10. doi:10.3238/arztebl.2020.0300; Brandt T, Dieterich M. The dizzy patient: don't forget disorders of the central vestibular system. Nat Rev Neurol. 2017 Jun;13(6):352-62. doi:10.1038/nrneurol.2017.58. Epub 2017 Apr 21.; Hallett M, Aybek S, Dworetzky BA, et al. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022 Jun;21(6):537-50. doi:10.1016/S1474-4422(21)00422-1. Epub 2022 Apr 14.; Watson M, Woodward J, Strom LA. The Financial Burden of Functional Neurological Disorders. Curr Neurol Neurosci Rep. 2023 Oct;23(10):637-43. doi:10.1007/s11910-023-01298-8. Epub 2023 Sep 11.; Stone J, Hallett M, Carson A, et al. Functional disorders in the Neurology section of ICD-11: A landmark opportunity. Neurology. 2014 Dec 9;83(24):2299-301. doi:10.1212/WNL.0000000000001063; Gelauff J, Stone J. Prognosis of functional neurologic disorders. Handb Clin Neurol. 2016;139:523-41. doi:10.1016/B978-0-12-801772-2.00043-6; Dieterich M, Staab JP. Functional dizziness: from phobic postural vertigo and chronic subjective dizziness to persistent postural-perceptual dizziness. Curr Opin Neurol. 2017 Feb;30(1):107-13. doi:10.1097/WCO.0000000000000417; Staab JP, Eckhardt-Henn A, Horii A, et al. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Barany Society. J Vestib Res. 2017;27(4):191-208. doi:10.3233/VES-170622; Wang A, Zhou G, Lipson S, et al. Multifactorial Characteristics of Pediatric Dizziness and Imbalance. Laryngoscope. 2021 Apr;131(4):E1308-E1314. doi:10.1002/lary.29024. Epub 2020 Aug 18.; Azzi JL, Khoury M, Seguin J, et al. Characteristics of persistent postural perceptual dizziness patients in a multidisciplinary dizziness clinic. J Vestib Res. 2022;32(3):285-93. doi:10.3233/VES-190749; Staab JP. Psychiatric Considerations in the Management of Dizzy Patients. Adv Otorhinolaryngol. 2019;82:170-9. doi:10.1159/000490286. Epub 2019 Jan 15.; Trinidade A, Cabreira V, Goebel JA, et al. Predictors of persistent postural-perceptual dizziness (PPPD) and similar forms of chronic dizziness precipitated by peripheral vestibular disorders : a systematic review. J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):904-15. doi:10.1136/jnnp-2022-330196. Epub 2023 Mar 20.; Kabaya K, Tamai H, Okajima A, et al. Presence of exacerbating factors of persistent perceptual-postural dizziness in patients with vestibular symptoms at initial presentation. Laryngoscope Investig Otolaryngol. 2022 Jan 25;7(2):499-505. doi:10.1002/lio2.735; Padovan L, Becker-Bense S, Flanagin VL, et al. Anxiety and physical impairment in patients with central vestibular disorders. J Neurol. 2023 Nov;270(11):5589-99. doi:10.1007/s00415-023-11871-3. Epub 2023 Aug 8.; Castro P, Bancroft MJ, Arshad Q, Kaski D. Persistent Postural-Perceptual Dizziness (PPPD) from Brain Imaging to Behaviour and Perception. Brain Sci. 2022 Jun 8;12(6):753. doi:10.3390/brainsci12060753; Jiang W, Sun J, Xiang J, et al. Altered Neuromagnetic Activity in Persistent Postural-Perceptual Dizziness: A Multifrequency Magnetoencephalography Study. Front Hum Neurosci. 2022 Mar 8;16:759103. doi:10.3389/fnhum.2022.759103; Dieterich M, Brandt T. Central vestibular networking for sensorimotor control, cognition, and emotion. Curr Opin Neurol. 2024 Feb 1;37(1):74-82. doi:10.1097/WCO.0000000000001233. Epub 2023 Nov 30.; Li K, Si L, Cui B, et al. Altered intra- and inter-network functional connectivity in patients with persistent postural-perceptual dizziness. Neuroimage Clin. 2020;26:102216. doi:10.1016/j.nicl.2020.102216. Epub 2020 Feb 18.; Yagi C, Morita Y, Kitazawa M, et al. Subtypes of Persistent Postural-Perceptual Dizziness. Front Neurol. 2021 Apr 16;12:652366. doi:10.3389/fneur.2021.652366; Bigelow RT, Semenov YR, du Lac S, et al. Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):367-72. doi:10.1136/jnnp-2015-310319. Epub 2015 Apr 17.; Scarff JR, Lippmann S. Treating Psychiatric Symptoms in Persistent Postural Perceptual Dizziness. Innov Clin Neurosci. 2023 Dec 1;20(10-12):49-54.; Teh CS, Abdullah NA, Kamaruddin NR, et al. Home-based Vestibular Rehabilitation: A Feasible and Effective Therapy for Persistent Postural Perceptual Dizziness (A Pilot Study). Ann Otol Rhinol Laryngol. 2023 May;132(5):566-77. doi:10.1177/00034894221111408. Epub 2022 Jul 6.; Зайцева ОВ, Оверченко КВ, Хирнеткина АФ. Вестибулярная мигрень в структуре головокружения: современные представления. Лечащий врач. 2019;(10):20-4. Доступно по ссылке: https://cyberleninka.ru/article/n/vestibulyarnaya-migren-v-strukture-golovokruzheniya-sovremennye-predstavleniya.; Шаповалова МВ, Замерград МВ, Гусева АЛ, Байбакова ЕВ. Двусторонняя вестибулопатия у пациентов пожилого возраста. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2020;120(10-2):16-21. doi:10.17116/jnevro202012010216.; Шевченко ЕВ, Рамазанов ГР, Петриков СС. Клиническая и инструментальная диагностика при остро возникшем головокружении. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2021;10(1):48-57. doi:10.23934/2223-9022-2021-10-1-48-57.; Дюкова ГМ, Крюков АИ, Макаров СА и др. Способ прогнозирования развития функционального головокружения после приступа доброкачественного пароксизмального позиционного головокружения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(5):120-5. doi:10.17116/jnevro2021121051120.; Застенская ЕН, Антоненко ЛМ. Коморбидные расстройства и терапия при персистирующем постуральном перцептивном головокружении. Неврология, нейропсихиатрия, психосоматика. 2023;15(4):66-73. doi:10.14412/2074-2711-2023-466-73.; Herdman D, Evetovits A, Everton HD, Murdin L. Is 'persistent postural perceptual dizziness' a helpful diagnostic label? A qualitative exploratory study. J Vestib Res. 2021;31(1):11-21. doi:10.3233/VES-201518; Waterston J, Chen L, Mahony K, et al. Persistent Postural-Perceptual Dizziness: Precipitating Conditions, Co-morbidities and Treatment With Cognitive Behavioral Therapy. Front Neurol. 2021 Dec 24;12:795516. doi:10.3389/fneur.2021.795516; Axer H, Finn S, Wassermann A, et al. Multimodal treatment of persistent postural-perceptual dizziness. Brain Behav. 2020 Dec;10(12):e01864. doi:10.1002/brb3.1864. Epub 2020 Sep 28.; Kaski D. Neurological update: dizziness. J Neurol. 2020 Jun;267(6):1864-9. doi:10.1007/s00415-020-09748-w. Epub 2020 Mar 4.; Herdman D, Norton S, Murdin L, et al. The INVEST trial: a randomised feasibility trial of psychologically informed vestibular rehabilitation versus current gold standard physiotherapy for people with Persistent Postural Perceptual Dizziness. J Neurol. 2022 Sep;269(9):4753-63. doi:10.1007/s00415-022-11107-w. Epub 2022 Apr 10.; Teh CS, Prepageran N. The impact of disease duration in persistent postural-perceptual dizziness (PPPD) on the quality of life, dizziness handicap and mental health. J Vestib Res. 2022;32(4):373-80. doi:10.3233/VES-210087; Nada EH, Ibraheem OA, Hassaan MR. Vestibular Rehabilitation Therapy Outcomes in Patients With Persistent Postural-Perceptual Dizziness. Ann Otol Rhinol Laryngol. 2019 Apr;128(4):323-9. doi:10.1177/0003489418823017. Epub 2019 Jan 4.; Thompson KJ, Goetting JC, Staab JP, Shepard NT. Retrospective review and telephone follow-up to evaluate a physical therapy protocol for treating persistent postural-perceptual dizziness: A pilot study. J Vestib Res. 2015;25(2):97-103; quiz 103-4. doi:10.3233/VES-150551; Whitney SL, Sparto PJ, Furman JM. Vestibular Rehabilitation and Factors That Can Affect Outcome. Semin Neurol. 2020 Feb;40(1):165-72. doi:10.1055/s-0039-3402062. Epub 2019 Dec 30.; Yu YC, Xue H, Zhang YX, Zhou J. Cognitive Behavior Therapy as Augmentation for Sertraline in Treating Patients with Persistent Postural-Perceptual Dizziness. Biomed Res Int. 2018 Mar 7;2018:8518631. doi:10.1155/2018/8518631; Webster KE, Kamo T, Smith L, et al. Non-pharmacological interventions for persistent postural-perceptual dizziness (PPPD). Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD015333. doi:10.1002/14651858.CD015333.pub2; Singh K, Garcia-Gomar MG, Cauzzo S, et al. Structural connectivity of autonomic, pain, limbic, and sensory brainstem nuclei in living humans based on 7 Tesla and 3 Tesla MRI. Hum Brain Mapp. 2022 Jul;43(10):3086-112. doi:10.1002/hbm.25836. Epub 2022 Mar 19.; Soto E, Vega R, Sesena E. Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res. 2013;23(3):119-37. doi:10.3233/VES-130494; Hoppes CW, Huppert TJ, Whitney SL, et al. Changes in Cortical Activation During Dual-Task Walking in Individuals With and Without Visual Vertigo. J Neurol Phys Ther. 2020 Apr;44(2):156-63. doi:10.1097/NPT.0000000000000310; Li M, Yeh FC, Zeng Q, et al. The trajectory of the medial longitudinal fasciculus in the human brain: A diffusion imaging-based tractography study. Hum Brain Mapp. 2021 Dec 15;42(18):6070-86. doi:10.1002/hbm.25670. Epub 2021 Oct 1.; Waselus M, Valentino RJ, Van Bockstaele EJ. Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J Chem Neuroanat. 2011 Jul;41(4):266-80. doi:10.1016/j.jchemneu.2011.05.011. Epub 2011 May 30.; McCall AA, Miller DM, Yates BJ. Descending Influences on Vestibulospinal and Vestibulosympathetic Reflexes. Front Neurol. 2017 Mar 27;8:112. doi:10.3389/fneur.2017.00112; Ahmed RU, Edgerton VR, Li S, et al. Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats. Dose Response. 2021 doi:10.1177/1559325821998136; Develle Y, Leblond H. Biphasic Effect of Buspirone on the H-Reflex in Acute Spinal Decerebrated Mice. Front Cell Neurosci. 2020 Jan 15;13:573. doi:10.3389/fncel.2019.00573; Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun 21;1461:111-8. doi:10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.; Villas-Boas GR, Lavorato SN, Paes MM, et al. Modulation of the serotonergic receptosome in the treatment of anxiety and depression : a narrative review of the experimental evidence. Pharmaceuticals (Basel). 2021;14(2):148. doi:10.3390/ph14020148; Kikuchi T, Maeda K, Suzuki M, et al. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol Rep. 2021 Jun;41(2):134-43. doi:10.1002/npr2.12180. Epub 2021 May 7.; Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? Expert Opin Drug Discov. 2013 Dec;8(12):1529-39. doi:10.1517/17460441.2013.855195. Epub 2013 Nov 7.; Salaciak K, Pytka K. Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases? Pharmacol Ther. 2021 Nov;227:107872. doi:10.1016/j.pharmthera.2021.107872. Epub 2021 Apr 24.; Smith ALW, Harmer CJ, Cowen PJ, Murphy SE. The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression. CNS Drugs. 2023 Jul;37(7):571-85. doi:10.1007/s40263-023-01014-7. Epub 2023 Jun 29.; Vegas-Suarez S, Morera-Herreras T, Requejo C, et al. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation. Front Pharmacol. 2022 Aug 30;13:953652. doi:10.3389/fphar.2022.953652; Garrett AR, Hawley JS. SSRI-associated bruxism : A systematic review of published case reports. Neurol Clin Pract. 2018 Apr;8(2):135-41. doi:10.1212/CPJ.0000000000000433; Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry. 1999 Dec;60(12):857-60. doi:10.4088/jcp.v60n1209; Prisco V, Iannaccone T, Di Grezia G. Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism. Eur Psychiatry. 2017;41(S1):s855-s855. doi:10.1016/j.eurpsy.2017.01.1701; Остроумова ОД, Максимов МЛ, Замерград МВ и др. Оценка фармакокинетических параметров, безопасности и переносимости препарата Веспирейт® при его однократном и многократном приемах: результаты клинического исследования I фазы. Неврология, нейропсихиатрия, психосоматика. 2023;15(4):53-65. doi:10.14412/2074-2711-2023-4-53-65.; Lacour M. Restoration of vestibular function: basic aspects and practical advances for rehabilitation. Curr Med Res Opin. 2006 Sep;22(9):1651-9. doi:10.1185/030079906X115694; Choi S-Y, Choi J-H, Oh EH, et al. Effect of vestibular exercise and optokinetic stimulation using virtual reality in persistent postural-perceptual dizziness. Sci Rep. 2021 Jul 14;11(1):14437. doi:10.1038/s41598-021-93940-z; Kristiansen L, Magnussen L, Juul-Kristensen B, et al. Feasibility of integrating vestibular rehabilitation and cognitive behaviour therapy for people with persistent dizziness. Pilot Feasibility Stud. 2019 May 20:5:69. doi:10.1186/s40814-019-0452-3
-
2Academic Journal
Authors: M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko, М. В. Замерград, В. А. Парфенов, А. С. Агафьина, Н. В. Лямина, М. М. Гаврик, Л. Р. Кучумова, Е. Р. Баранцевич, В. С. Краснов, А. А. Иванова, А. Л. Владыкин, К. А. Ищенко
Contributors: This article has been supported by Valenta Pharm, Статья спонсируется компанией «Валента Фарм»
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 5 (2023); 20-34 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 5 (2023); 20-34 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-5
Subject Terms: клиническое исследование, functional dizziness, persistent postural-perceptual dizziness, chronic subjective dizziness, phobic postural vertigo, buspirone, Vespireit®, prolonged-release tablets, clinical trial, функциональное головокружение, персистирующее постурально-перцептивное головокружение, хроническое субъективное головокружение, постуральная фобическая неустойчивость, буспирон, Веспирейт®, таблетки с пролонгированным высвобождением
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2101/1581; Dieterich M, Staab JP, Brandt T. Functional (psychogenic) dizziness. Handb Clin Neurol. 2016;139:447-68. doi:10.1016/B978-0-12801772-2.00037-0; Obermann M, Bock E, Sabev N, et al. Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care: the Dizziness and Vertigo Registry (DiVeR) Study. J Neurol. 2015 Sep;262(9):2083-91. doi:10.1007/s00415-015-7803-7. Epub 2015 Jun 20.; Brandt T, Dieterich M, Strupp M. Vertigo and dizziness: common complaints. 2nd ed. London: Springer-Verlag; 2013.; Stone J. Persistent posturo-perceptual dizziness (PPPD) (functional dizziness). 2016. Available from: https://www.neurosymptoms.org/wpcontent/uploads/2020/11/Dizziness-PPPDinformation-sheet-v2.pdf; Bittar RS, Lins EM. Clinical characteristics of patients with persistent postural-perceptual dizziness. Braz J Otorhinolaryngol. 2015 MayJun;81(3):276-82. doi:10.1016/j.bjorl.2014.08.012. Epub 2014 Sep 6.; Holle D, Schulte-Steinberg B, Wurthmann S, et al. Persistent PosturalPerceptual Dizziness: A Matter of Higher, Central Dysfunction? PLoS One. 2015 Nov 16;10(11):e0142468. doi:10.1371/journal.pone.0142468; Webster KE, Harrington-Benton NA, Judd O, et al. Pharmacological interventions for persistent postural-perceptual dizziness (PPPD). Cochrane Database Syst Rev. 2023 Mar 9;3(3):CD015188. doi:10.1002/14651858.CD015188.pub2; Staab JP, Ruckenstein MJ, Solomon D, Shepard NT. Serotonin reuptake inhibitors for dizziness with psychiatric symptoms. Arch Otolaryngol Head Neck Surg. 2002 May;128(5):554-60. doi:10.1001/archotol.128.5.554; Staab JP, Ruckenstein MJ, Amsterdam JD. A prospective trial of sertraline for chronic subjective dizziness. Laryngoscope. 2004 Sep;114(9):1637-41. doi:10.1097/00005537200409000-00025; Horii A, Mitani K, Kitahara T, et al. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness. Otol Neurotol. 2004 Jul;25(4):536-43. doi:10.1097/00129492-200407000-00022; Horii A, Uno A, Kitahara T, et al. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res. 2007;17(1):1-8.; Simon NM, Parker SW, Wernick-Robinson M, et al. Fluoxetine for vestibular dysfunction and anxiety: a prospective pilot study. Psychosomatics. 2005 Jul-Aug;46(4):334-9. doi:10.1176/appi.psy.46.4.334; Colombo B, Teggi R, editors. Vestibular migraine and related syndromes. Springer; 2014.; Babu S, Schutt ChA, Bojrab DI, editors. Diagnosis and treatment of vestibular disorders. Springer; 2019.; Gold D. Neuro-ophthalmology and neuro-otology. A Case-Based Guide for Clinicians and Scientists. Springer; 2022.; Soto E, Vega R, Sesena E. Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res. 2013;23(3):119-37. doi:10.3233/VES-130494; Han L, Wu KL, Kwan PY, et al. 5-HT1A receptor-mediated attenuation of synaptic transmission in rat medial vestibular nucleus impacts on vestibular-related motor function. J Physiol. 2021 Jan;599(1):253-67. doi:10.1113/JP282313; Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a doubleblind, placebo-controlled pilot study. Med Sci Monit. 2006 Jan;12(1):PI1-7. Epub 2005 Dec 19.; Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos. 1989 Nov-Dec;17(6):634-40.; Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986 Aug;32(2):114-29. doi:10.2165/00003495198632020-00002; Riblet LA, Eison AS, Eison MS, et al. Neuropharmacology of buspirone. Psychopathology. 1984;17 Suppl 3:69-78. doi:10.1159/000284133; Product monograph – Buspirone (buspirone hydrochloride tablets, USP, 5 mg and 10 mg). Pharmascience Inc.; 2016.; Sakr A, Andheria M. Pharmacokinetics of buspirone extended-release tablets: a singledose study. J Clin Pharmacol. 2001 Jul;41(7):783-9. doi:10.1177/00912700122010582; Study report: a randomized, open label, three-treatment, three-period, three-sequence, crossover, pilot, comparative bioavailability study of buspirone 15 mg sustained release tablets [two different formulations – VPH016100 and VPH016101] of JSC Valenta Pharmaceuticals, Russia and three tablets of Buspin tablet [buspirone] 5 mg of Intas Pharmaceuticals, India, in healthy adult subjects under fasting condition. Version No.: 6.0, Date: 16-Dec-2015.; Открытое, трехэтапное исследование переносимости, безопасности и фармакокинетических параметров препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия) при однократном применении с изучением фактора приема пищи и многократном применении у здоровых добровольцев. Отчет о клиническом исследовании. Тбилиси; 2019.; Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun 21;1461:111-8. doi:10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.; Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. doi:10.1016/s0014-2999(98)00483-x; Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol. 1991 Sep;69(3):149-56. doi:10.1111/j.16000773.1991.tb01289.x; Buspirone [Electronic resource]. DrugBank. Available from: https://www.drugbank.ca/drugs/DB00490 (accessed 01.05.2019).; Carli M, Prontera C, Samanin R. Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br J Pharmacol. 1989 Apr;96(4):829-36. doi:10.1111/j.14765381.1989.tb11891.x; Adell A, Sarna GS, Hutson PH, Curzon G. An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. Br J Pharmacol. 1989 May;97(1):206-12. doi:10.1111/j.14765381.1989.tb11943.x; Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol. 1989 Feb;96(2):283-90. doi:10.1111/j.14765381.1989.tb11815.x; Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1(1):3-9. doi:10.1002/syn.890010103; Sillar KT, Simmers AJ. Presynaptic inhibition of primary afferent transmitter release by 5-hydroxytryptamine at a mechanosensory synapse in the vertebrate spinal cord. J Neurosci. 1994 May;14(5 Pt 1):2636-47. doi:10.1523/JNEUROSCI.14-05-02636.1994; McNaughton N, Panickar KS, Logan B. The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. Pharmacol Biochem Behav. 1996 May;54(1):51-6. doi:10.1016/00913057(95)02129-9; Hodges H, Green S, Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology (Berl). 1987;92(4):491-504. doi:10.1007/BF00176484; Drescher MJ, Cho WJ, Folbe AJ, et al. An adenylyl cyclase signaling pathway predicts direct dopaminergic input to vestibular hair cells. Neuroscience. 2010 Dec 29;171(4):105474. doi:10.1016/j.neuroscience.2010.09.051. Epub 2010 Sep 29.; Gallagher JP, Phelan KD, Shinnick-Gallagher P. Modulation of excitatory transmission at the rat medial vestibular nucleus synapse. Ann N Y Acad Sci. 1992 May 22;656:630-44. doi:10.1111/j.17496632.1992.tb25241.x; Andrianov GN, Ryzhova IV, Tobias TV. Dopaminergic modulation of afferent synaptic transmission in the semicircular canals of frogs. Neurosignals. 2009;17(3):222-8. doi:10.1159/000224632. Epub 2009 Jun 17.; New JS. The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev. 1990 JulSep;10(3):283-326. doi:10.1002/med.2610100302; Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology. 6th ed. Churchill Livingstone; 2008.; Проспективное двухэтапное мультицентровое рандомизированное двойное слепое плацебо-контролируемое исследование в параллельных группах по оценке эффективности, безопасности и переносимости лекарственного препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия), при его применении у пациентов с синдромом вегетативной дисфункции, сопровождающимся головокружением. Протокол исследования № БУСП-02-02-2019. Отчет о клиническом исследовании II фазы. 21.01.2020.; Двойное слепое плацебо-контролируемое многоцентровое рандомизированное клиническое исследование по оценке эффективности и безопасности применения препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия) у пациентов с синдромом вегетативной дисфункции, сопровождающимся головокружением. Протокол исследования БУСП-03-03-2021. Отчет о клиническом исследовании 2022 г.; Koppelaar-van Eijsden HM, Schermer TR, Bruintjes TD. Measurement Properties of the Dizziness Handicap Inventory: A Systematic Review. Otol Neurotol. 2022 Mar 1;43(3):e282-e297. doi:10.1097/MAO.0000000000003448; Available from: https://clinicaltrials.gov/ct2/show/NCT05430217?term=buspirone&cond=buspirone&cntry=RU&draw=2&rank=1; ICD-11 for Mortality and Morbidity Statistics (Version: 02/2022). Available from: https://icd.who.int/browse11/lm/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f579898286; Rocco PL, Giavedoni A, Pacella G. Withdrawal from benzodiazepines in a hospital setting: An open trial with buspirone. Curr Ther Res. 1992;52(3):386-9.; Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety – a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21(3):124-30. doi:10.1159/000118565; Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996 Jul;57(7):287-91.; Fulton B, Brogden RN. Buspirone. CNS Drugs. 1997;7(1):68-88.; Laakmann G, Schüle C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998 Apr;136(4):357-66. doi:10.1007/s002130050578; Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999 Feb;19(1):86-93. doi:10.1097/00004714199902000-00014; Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22(2):101-14. doi:10.2165/00002512200522020-00002; Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016 Jan 13;2016:1002.; BuSpar® (Bristol-Myers Squibb Company, USA). U.S. Food and Drug Administration (FDA). Drug label, revised November 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf; Инструкция по медицинскому применению лекарственного препарата Спитомин® таблетки 5 мг и 10 мг.